Fidelity Disruptive Medicine ETFFidelity Disruptive Medicine ETFFidelity Disruptive Medicine ETF

Fidelity Disruptive Medicine ETF

No trades
See on Supercharts

Key stats


Assets under management (AUM)
‪53.05 M‬USD
Fund flows (1Y)
‪2.35 M‬USD
Dividend yield (indicated)
0.47%
Discount/Premium to NAV
−0.2%
Shares outstanding
‪2.22 M‬
Expense ratio
0.50%

About Fidelity Disruptive Medicine ETF


Issuer
FMR LLC
Brand
Fidelity
Inception date
Jun 12, 2023
Structure
Open-Ended Fund
Index tracked
No Underlying Index
Replication method
Physical
Management style
Active
Dividend treatment
Distributes
Distribution tax treatment
Qualified dividends
Income tax type
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Primary advisor
Fidelity Management & Research Co. LLC
Distributor
Fidelity Distributors Co. LLC
FMED seeks long-term capital appreciation by utilizing proprietary disruptive strategies in identifying companies involved in disruptive technologies for its portfolio. Disruptive technologies are innovations that may reshape how businesses currently deliver their services and operate, potentially displacing industry leaders over time. The fund primarily invests in growth and value stocks of companies tied with disruptive innovation in health care globally. This includes robotic surgery, cell and gene therapy, genomics, rare diseases, medical devices and equipment, immunotherapy, technology-based healthcare platforms, advanced diagnostics, and consumer wellness. The adviser uses fundamental analysis, as well as economic and market conditions for its portfolio construction. The adviser may buy, sell, and hold decisions at their discretion. FMED converted from a mutual fund to an actively managed ETF, with $44 million in assets.

Classification


Asset Class
Equity
Category
Sector
Focus
Health care
Niche
Broad-based
Strategy
Active
Geography
Global
Weighting scheme
Proprietary
Selection criteria
Proprietary

Returns


1 month3 monthsYear to date1 year3 years5 years
Price performance
NAV total return

What's in the fund


As of June 27, 2025
Exposure type
StocksBonds, Cash & Other
Health Technology
Stocks99.59%
Health Technology75.16%
Technology Services9.03%
Health Services6.55%
Finance1.37%
Bonds, Cash & Other0.41%
Mutual fund8.53%
Cash−8.12%
Stock breakdown by region
84%14%1%
North America84.00%
Europe14.49%
Asia1.51%
Latin America0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings

Dividends


Dividend payout history

Assets under management (AUM)



Fund Flows



Frequently Asked Questions


FMED invests in stocks. The fund's major sectors are Health Technology, with 81.26% stocks, and Technology Services, with 9.77% of the basket. The assets are mostly located in the North America region.
FMED last dividends amounted to 0.11 USD. The quarter before, the issuer paid 0.00 USD in dividends, which shows a 99.11% increase.
FMED assets under management is ‪53.05 M‬ USD. It's risen 7.41% over the last month.
FMED fund flows account for ‪2.35 M‬ USD (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
Yes, FMED pays dividends to its holders with the dividend yield of 0.47%. The last dividend (Dec 24, 2024) amounted to 0.11 USD. The dividends are paid quarterly.
FMED shares are issued by FMR LLC under the brand Fidelity. The ETF was launched on Jun 12, 2023, and its management style is Active.
FMED expense ratio is 0.50% meaning you'd have to pay 0.50% of your investment to help manage the fund.
FMED follows the No Underlying Index. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
FMED invests in stocks.
FMED price has risen by 2.86% over the last month, and its yearly performance shows a 0.04% increase. See more dynamics on FMED price chart.
NAV returns, another gauge of an ETF dynamics, have risen by 2.63% over the last month, showed a 1.44% increase in three-month performance and has increased by 0.26% in a year.
FMED trades at a premium (0.24%) meaning the ETF is trading at a higher price than the calculated NAV.